Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | metal transporter, putative | 0.058 | 1 | 0.5 |
Mycobacterium tuberculosis | Divalent cation-transport integral membrane protein MntH (BRAMP) (MRAMP) | 0.0359 | 0.3861 | 1 |
Toxoplasma gondii | divalent metal transporter, putative | 0.058 | 1 | 0.5 |
Mycobacterium leprae | possible membrane transport protein | 0.0222 | 0.0065 | 0.0168 |
Mycobacterium ulcerans | divalent cation-transport integral membrane protein | 0.0222 | 0.0065 | 0.0065 |
Loa Loa (eye worm) | hypothetical protein | 0.058 | 1 | 0.5 |
Echinococcus granulosus | divalent metal transporter DMT1B | 0.058 | 1 | 0.5 |
Onchocerca volvulus | Protein Malvolio homolog | 0.058 | 1 | 0.5 |
Echinococcus multilocularis | divalent metal transporter DMT1B | 0.058 | 1 | 0.5 |
Plasmodium falciparum | transporter, putative | 0.058 | 1 | 0.5 |
Mycobacterium leprae | DIVALENT CATION-TRANSPORT INTEGRAL MEMBRANE PROTEIN MNTH (BRAMP) (MRAMP) | 0.0359 | 0.3861 | 1 |
Mycobacterium ulcerans | manganese transport protein MntH | 0.058 | 1 | 1 |
Schistosoma mansoni | divalent metal transporter DMT1B | 0.058 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.058 | 1 | 0.5 |
Mycobacterium ulcerans | divalent cation-transport integral membrane protein | 0.0222 | 0.0065 | 0.0065 |
Schistosoma mansoni | divalent metal transporter DMT1B | 0.058 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.